Product Program year 2021 Source: CMS Open Payments

Insulin Lispro

Drug Diabetes

NDC 66733-773-01

Open in the dashboard

General payments

$489

35 payments

Research payments

$0

0 payments

Through program year 2021, $489 in general payments and $0 in research payments were reported against Insulin Lispro (Diabetes).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2021 General $489 35

Breakdown

Who paid General payments · program year 2021
  1. Lilly USA, LLC $489 35 payments
Top recipients General payments · program year 2021
  1. Brian Heineman Adolescent Medicine · Grinnell, IA $78 16% · 6 payments
  2. Kenneth Cohen Internal Medicine · Lakewood, CO $40 8% · 1 payment
  3. Samantha Smith Physician Assistant, Medical · Brooklyn, IA $40 8% · 3 payments
  4. Kyle Hawkins Physician Assistant · Iowa City, IA $37 8% · 3 payments
  5. Emily Wagner Physician Assistant · Brooklyn, IA $35 7% · 3 payments

The top 5 of 18 recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Family Medicine $165 34% · 7 practitioners
  2. Physician Assistant $98 20% · 3 practitioners
  3. Adolescent Medicine Family Medicine $78 16% · 1 practitioner
  4. Internal Medicine $73 15% · 3 practitioners
  5. Physician Assistant, Medical Physician Assistant $40 8% · 1 practitioner

The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. Iowa $319 65% · 9 recipients
  2. Nebraska $70 14% · 3 recipients
  3. Kansas $44 9% · 4 recipients
  4. Colorado $40 8% · 1 recipient
  5. Missouri $15 3% · 1 recipient

Each share is of general payments naming this product in 2021 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

2,135,220

Prescriptions dispensed, refills included

Drug cost

$538,041,905

Paid at the pharmacy, in all

Medicare Part D drugs matched to Insulin Lispro, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Humalog Kwikpen U-100 Insulin Lispro Same name 31,197 946,211 $234,056,963
Humalog Kwikpen U-200 Insulin Lispro Same name 3,540 69,162 $112,438,184
Insulin Lispro Kwikpen U-100 Insulin Lispro Same name 19,765 525,043 $94,048,495
Humalog Insulin Lispro Same name 11,813 330,284 $66,882,869
Admelog Solostar Insulin Lispro Same name 3,068 62,526 $12,834,563
Insulin Lispro Same name 6,946 163,600 $9,836,284
Insulin Lispro Protamine Mix Insulin Lispro Protamin/Lispro Similar name 993 17,969 $4,645,711
Admelog Insulin Lispro Same name 901 16,538 $2,777,396
Humalog Junior Kwikpen Insulin Lispro Same name 147 2,572 $367,055
Insulin Lispro Junior Kwikpen Insulin Lispro Same name 85 1,232 $140,495
Humalog Tempo Pen U-100 Insulin Lispro Same name 6 83 $13,891

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 829 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Carlos Martinez Rivera Endocrinology PR 2,356 $526,126 None on record
Robert Pearlstein Internal Medicine PA 1,150 $76,703 None on record
Brandon Roscoe Family Practice PA 1,025 $65,988 None on record
Vasdev Lohano Endocrinology IN 995 $268,859 None on record
Eugenio Angueira-Serrano Endocrinology FL 987 $303,785 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 829 with Patron
35 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record